

2010

Hemodynamic effects of insulin and dextrose in healthy volunteers

Stephan Brenner

Washington University School of Medicine in St. Louis

Stacey House

Washington University School of Medicine in St. Louis

Amanda Cannarozzi

Washington University School of Medicine in St. Louis

S. Eliza Halcomb

Washington University School of Medicine in St. Louis

Follow this and additional works at: http://digitalcommons.wustl.edu/em_conf

Recommended Citation

Brenner, Stephan; House, Stacey; Cannarozzi, Amanda; and Halcomb, S. Eliza, "Hemodynamic effects of insulin and dextrose in healthy volunteers" (2010). *Conference Abstracts and Posters*. Paper 4.
http://digitalcommons.wustl.edu/em_conf/4

This Presentation Paper is brought to you for free and open access by the Division of Emergency Medicine/Emergency Care Research Section at Digital Commons@Becker. It has been accepted for inclusion in Conference Abstracts and Posters by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.

Hemodynamic Effects of Insulin and Dextrose in Healthy Volunteers

Stephan Brenner MD, MPH; Stacey House MD, Amanda Cannarozzi MD, S. Eliza Halcomb MD
Division of Emergency Medicine, Washington University School of Medicine, St. Louis, Missouri

INTRODUCTION

The combination of high dose insulin and glucose has been repeatedly used in various cardiac conditions (chronic heart failure (1), acute myocardial infarction (AMI) (2), post-ischemic reperfusion (3), cardiac surgery (4)). It also has become part of the antidotal treatment of overdose with calcium channel and beta-adrenergic blocking agents (5).

Insulin/glucose effects on distressed myocardium have been studied.

Whereas hyperglycemia has shown increased mortality in patients with cardiac ischemia, some evidence suggests cardioprotective effects of insulin at the myocyte level given a strict normoglycemic metabolic state can be maintained (6).

Little, however, is understood about the impact of insulin/glucose on healthy myocardium. With this study we tried to assess the effects of insulin-euglycemia treatment on hemodynamics of healthy hearts in vivo.

METHODS

Ten (10) healthy, non-diabetic, females were enrolled in a prospective double blind cross-over trial. Each volunteer received 10 units regular insulin with 25 gm dextrose IV vs. placebo (0.9% saline IV). After each infusion cardiac parameters (heart rate, blood pressure, fractional shortening of the left ventricle) were measured every 15 min for one hour. ANOVA for repeated measures was calculated using insulin/glucose or placebo treatment as subject factors. Post-hoc paired t-tests were done when ANOVA analysis suggested a significant effect at an alpha = 0.05 level.

Measurements for fractional shortening were obtained by cardiac ultrasound. M mode images across the left ventricle (LV) in parasternal short axis probe position (see Image1) were recorded at the various time points. Fractional shortening was found to represent the best approximation of LV function given the type of images obtained.

In order to calculate the percentage of fractional shortening, end systolic diameter (ESD) and end diastolic diameter (EDD) were measured and computed in the following formula:

$$\left(\frac{EDD - ESD}{EDD} \right) \times 100$$




Image 1

Table 1: Participant Characteristics

	Average	Range
Age (years)	27	20 - 37
BMI (kg/m ²)	27.17	20.8 - 34.8
Baseline Blood Glucose Level (mg/dL)	94.8	81 - 127




Figure 1




Figure 2




Figure 3




Figure 4

Figures 1 - 4: Changes in heart rate, systolic blood pressure, diastolic blood pressure, and % fractional shortening respectively over time in the two intervention arms.

Data points represent population means, intervals represent standard errors around the population means for each set of measurements at the given time points.

RESULTS

For heart rate (HR), systolic blood pressure (SBP), and fractional ventricular shortening (FVS) no significant differences in group means could be detected.

There was a statistical significant difference towards lower diastolic blood pressures (DBP) in the insulin/glucose treatment arm (ANOVA $p = 0.004$). Paired t-test analysis calculated significant differences for DBP between the treatment arms at 15, 30, and 60 min ($p = 0.02, 0.04, \text{ and } 0.01$ respectively). However, the treatment effect was measured as a decrease in DBP of only 3.9-5.4 mmHg.

DISCUSSION

Best possible homogeneity of the study participants was achieved by selecting young, healthy, same sex individuals. Due to practical constraints, population size was kept small in this pilot study, which may impact the ability to detect a significant difference in means of the measured hemodynamic parameters.

We used a low-dose insulin one time bolus regimen in this study. Our study participants received 0.13 IU/kg regular insulin bolus in average. Cardioprotective effects reported in the literature were observed with higher or different insulin regimens. The DIGAMI study insulin protocol used 5 IU/hr bolus initially with rate adjustments over time according to patients blood glucose levels. Recommended treatment doses used in calcium channel and beta-adrenergic blocking agent overdoses are 1 IU/kg insulin bolus followed by a 0.5 IU/kg/hr rate. Therefore, the lack of significant hemodynamic effects in this study might be in part contributed to the low dose insulin regimen used.

Finally, significant effects of insulin on hemodynamics might just be subtle in healthy myocardium, whereas significant improvements of cardiac function occurs only in distressed or pathologic cardiac conditions.

CONCLUSION

In this study, low-dose insulin-euglycemia treatment seems to have little or no effect on the hemodynamic parameters of healthy, non-stressed hearts. Therefore, cardioprotective effects from insulin/glucose might be more evident with use of high-dose insulin regimens or under conditions with maximal cardiac distress.

REFERENCES

- (1) Parsonage WA, Hetmanski D, Cowley AJ. Beneficial haemodynamic effects of insulin in chronic heart failure. *Heart* 2001;85:508-13.
- (2) Malmberg K, et al. Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. *BMJ* 1997;314:1512-5.
- (3) Gao F et al. Nitric Oxide Mediates the Antiapoptotic Effect of Insulin in Myocardial Ischemia-Reperfusion. *Circulation* 2002;105:1497-1502.
- (4) Svedjeholm R, Huljebant I, Hakanson E, Vanhanen I. Glutamate and high-dose insulin-potassium (GIK) in the treatment of severe cardiac failure after cardiac operations. *Ann Thorac Surg* 1995;59:S23-30.
- (5) Kerns W. Management of beta-adrenergic blocker and calcium channel antagonist toxicity. *Emerg Med Clin N Am* 2007;25:309-31.
- (6) Marfalla et al. Tight glycaemic control reduces heart inflammation and remodeling during acute myocardial infarction in hyperglycaemic patients. *J Am Coll Cardiol* 2009;53:1425-36.